1251931-22-2

Basic information

• Product Name: {2-[4-(4-bromo-1-methoxymethyl-5-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimethyl-amine
• Synonyms: {2-[4-(4-bromo-1-methoxymethyl-5-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimethyl-amine
• CAS NO: 1251931-22-2
• Molecular Weight: 431.332
• Mol File: 1251931-22-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: {2-[4-(4-bromo-1-methoxymethyl-5-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimethyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: {2-[4-(4-bromo-1-methoxymethyl-5-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimethyl-amine(1251931-22-2)
• EPA Substance Registry System: {2-[4-(4-bromo-1-methoxymethyl-5-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimethyl-amine(1251931-22-2)

Safety Data

• Hazardous Substances Data: 1251931-22-2(Hazardous Substances Data)

Upstream product

• 1251931-21-1 {2-[4-(4,5-dibromo-1-methoxymethyl-1H-imidazol-2-yl)phenoxy]ethyl}dimethylamine 
• 1692-15-5 4-pyridylboronic acid 

Downstream Products

• 1251931-58-4 7-{2-[4-(2-dimethylaminoethoxy)-phenyl]-1-methoxymethyl-5-(pyridin-4-yl)-1H-imidazol-4-yl}-2,4,4a,5-tetrahydroindeno[1,2-c]pyridazin-3-one 
• 1251931-54-0 {2-[4-(5-{4-[1-(4-methoxybenzyl)-4-methyl-1H-pyrazol-3-yl]-phenyl}-1-methoxymethyl-4-(pyridin-4-yl)-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimethylamine 
• 1251931-55-1 3-(4-{2-[4-(2-dimethylaminoethoxy)-phenyl]-3-methoxymethyl-5-(pyridin-4-yl)-3H-imidazol-4-yl}-phenyl)-1-(4-methoxybenzyl)-1H-pyrazole-4-carbonitrile 
• 1251931-56-2 [2-(4-{4-[1-(4-methoxybenzyl)-4,5-dihydro-1H-benzo[g]indazol-7-yl]-1-methoxymethyl-5-(pyridin-4-yl)-1H-imidazol-2-yl}-phenoxy)-ethyl]-dimethylamine 
• 1251931-57-3 [2-(4-{4-[1-(4-methoxybenzyl)-1H-benzo[g]indazol-7-yl]-1-methoxymethyl-5-(pyridin-4-yl)-1H-imidazol-2-yl}-phenoxy)-ethyl]-dimethylamine 
• 1426082-99-6 6-{2-[4-(2-dimethylamino-ethoxy)-phenyl]-1-methoxymethyl-5-pyridin-4-yl-1H-imidazol-4-yl}-naphthalen-2-ol 
• 1426082-26-9 6-{2-[4-(2-dimethylamino-ethoxy)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-naphthalen-1-ol 
• 1426082-22-5 (2-{4-[5-(3-methanesulfinyl-benzo[b]thiophen-6-yl)-4-pyridin-4-yl-1H-imidazol-2-yl]-phenoxy}-ethyl)-dimethylamine 
• 1426082-20-3 dimethyl-[2-(4-{5-[3-(propane-1-sulfinyl)-benzo[b]thiophen-6-yl]-4-pyridin-4-yl-1H-imidazol-2-yl}-phenoxy)-ethyl]-amine 
• 1426082-18-9 C₂₈H₂₅F₃N₄O₂S 
• 1426082-17-8 C₂₈H₂₅F₃N₄O₂S 
• 1251931-23-3 {2-[4-(4-bromo-5-pyridin-4-yl-1H-imidazol-2-yl)-phenoxy]-ethyl}-dimethyl-amine 
• 1426082-28-1 6-{2-[4-(2-dimethylamino-ethoxy)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-naphthalene-2-carboxylic acid 
• 1426083-11-5 6-{2-[4-(2-dimethylamino-ethoxy)-phenyl]-5-pyridin-4-yl-3H-imidazol-4-yl}-2H-isoquinolin-1-one 

Relevant articles and documents

Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds

V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine-specific protein kinase that is mutated with high frequency in cutaneous melanoma, and many other cancers. Inhibition of mutant BRAF is an attractive therapeutic approach for the treatment of melanoma. A triarylimidazole BRAF inhibitor bearing a phenylpyrazole group (dimethyl-[2-(4-{5-[4-(1H-pyrazol-3-yl)-phenyl]-4-pyridin-4-yl-1H-imidazol-2-yl} -phenoxy)-ethyl]-amine, 1a) was identified as an active BRAF inhibitor. Based on this starting point, we synthesized a series of analogues leading to the discovery of 6-{2-[4-(4-methyl-piperazin-1-yl)-phenyl]-5-pyridin-4-yl-3H- imidazol-4-yl}-2,4-dihydro-indeno[1,2-c]pyrazole (1j), with nanomolar activity in three assays: inhibition of purified mutant BRAF activity in vitro; inhibition of oncogenic BRAF-driven extracellular regulated kinase (ERK) activation in BRAF mutant melanoma cell lines; and inhibition of proliferation in these cells.